Virginia’s Legislative Commission Explores Impact of Federal Cannabis Policy Changes
The Virginia legislative commission responsible for overseeing the state’s transition to a retail cannabis market met on Tuesday to discuss the potential effects of recent federal policy changes on the state’s cannabis industry. According to the National Conference on State Legislatures, many questions still remain unanswered.
In April, the federal government reclassified state-licensed medical cannabis from a Schedule I to a Schedule III drug, a change that acknowledges the substance’s medical benefits. Additionally, a federal spending bill passed in December narrowed the definition of legal hemp, a change that will take effect in November.
The reclassification of medical cannabis from a Schedule I to a Schedule III drug is expected to have a significant impact on medical cannabis dispensaries in Virginia. Historically, these dispensaries have been unable to benefit from business expense tax deductions, a situation that is set to change with the new classification. However, many questions still surround the details of this change and how it will affect the state’s cannabis industry.
As the state continues to navigate its transition to a retail cannabis market, the legislative commission will need to address these unanswered questions and provide clarity on the implications of federal policy changes for Virginia’s cannabis industry.
